The DEA Already Banned Kratom's Cousin Chemical. In Three Days, It Decides How Much of the Original Survives.

Ten years ago this fall, the DEA announced it was putting kratom’s active compounds into Schedule I — the same legal category as heroin — and gave the public thirty days’ warning before the ban took effect. It did not take effect. Advocacy groups organized petitions and phone campaigns, members of Congress wrote to the Attorney General, and in October 2016 acting DEA administrator Chuck Rosenberg withdrew the notice entirely, opting for public comment instead of emergency action. Kratom has been legal at the federal level, in a kind of permanent regulatory limbo, ever since.

The DEA learned one lesson from 2016: don’t try to ban the whole plant in one move. This year it’s banning a molecule instead — and asking the public to help it decide, gram by gram, how much of that molecule still counts as the plant.

That is the plain-English version of what’s happening right now with 7-hydroxymitragynine, known as 7-OH, and it is worth translating carefully because the policy itself is written to be confusing. Kratom is a tropical tree leaf, used for centuries in Southeast Asia and, more recently, sold across the U.S. as a supplement — people use it for pain, energy, opioid withdrawal management, and mood. Mitragynine is kratom’s main active compound. 7-OH is a minor, much more potent compound that occurs naturally in kratom leaf in tiny amounts — but that manufacturers have learned to concentrate into standalone extracts and shots that are functionally a different, stronger drug wearing kratom’s name. Products marketed as “7-OH shots” can carry doses many times higher than anything a person would get from chewing or brewing the leaf itself, and those concentrated products are what’s driving the current regulatory fight — not tea.

What actually happened, and what’s still pending

On August 26, 2026, DEA Administrator Terry Cole’s agency placed mitragynine pseudoindoxyl — MPGI — along with two related synthetic compounds, MGM-15 and MGM-16, into Schedule I. Those are lab-made derivatives, not something you’d get from leaf alone, and the industry response to that piece of the action has been muted — even kratom trade groups have generally agreed MPGI is a different animal worth regulating hard.

7-OH is the harder, more contested question, and it is not settled yet. Rather than an outright Schedule I ban, the Department of Health and Human Services’ Office of the Assistant Secretary for Health proposed a threshold: cap legal 7-OH concentration at 0.05% of a product by weight or volume — roughly one milligram of 7-OH per tablet. Virtually every concentrated 7-OH product currently sold blows past that number by a wide margin, so in practical terms the threshold would function as a near-ban on the extract-and-shot category while leaving traditional leaf powder and tea largely untouched. Whole-leaf kratom’s naturally occurring 7-OH content is a small fraction of a percent — well under the proposed cap — which is exactly why OASH is proposing a number instead of a blanket prohibition.

The comment period on that threshold was originally due to close in late August; neuroscientist and kratom-legality advocate Dr. Michele Ross petitioned for more time, and OASH granted a fifteen-day extension, pushing the deadline to September 10, 2026 — three days from when this piece is running. Comments go through regulations.gov under docket HHS-OASH-2026-0232-0001. OASH has been explicit that it is not accepting comments on kratom’s general safety, on permanent scheduling, or on any other policy question — only on where the numeric line should sit. That narrow scope is itself a signal: the agency has already decided a threshold is coming and is negotiating its size, not its existence.

The DEA has separately said it will use “enforcement discretion” for trace amounts of MPGI that occur naturally in botanical kratom leaf, so a bag of leaf powder won’t become federally illegal by accident. But the agency was careful to add that discretion “does not create a legal exemption” — meaning no individual seller or user gets a guarantee, only a stated intention that could change per officer, per case, per administration. If you sell or use kratom leaf products, that is the sentence to actually read twice, because it is doing the opposite of the reassurance it sounds like.

If you sell or use kratom leaf products, that is the sentence to actually read twice, because it is doing the opposite of the reassurance it sounds like.

The part that repeats

History doesn’t usually hand you a cleaner rhyme than this one. In 2016, the DEA tried the blunt instrument — Schedule I, thirty days, done — and public pressure broke it in six weeks. In 2026, the same agency is trying the scalpel: schedule the synthetic derivative outright, thread a concentration threshold through the substance that actually drives the market, and give thirty-odd days of public comment instead of thirty days of countdown to a ban. It’s a more durable strategy precisely because it’s harder to organize against — there’s no single villain sentence to rally a petition around, just a percentage. Advocacy groups that beat the 2016 ban with volume and outrage are having to learn, in 2026, to fight in the language of concentration thresholds and docket numbers instead.

For treatment providers and case managers, the practical takeaway is not “kratom is legal” or “kratom is banned” — it’s that the products your clients may already be using to self-manage opioid withdrawal or pain are about to sort into two very different legal categories on the same store shelf, and neither the store nor the client may know which is which yet. Screening for kratom use should now also mean asking what form — leaf, powder, or a labeled “7-OH” shot or tablet — because the risk profile, the dosing, and very soon the legal status are not the same product. That’s a five-minute addition to an intake conversation this week, not a policy position.

Whatever the number that lands on September 10 or after, it will arrive the same way the 1988 syringe-exchange ban and the 2016 kratom notice both did: as a federal answer to a state-by-state, person-by-person reality that doesn’t sort itself neatly by milligram. The people using 7-OH products to get through opioid withdrawal without returning to fentanyl are not going to stop needing an answer to that problem on September 11, whatever the docket says.